UK-based Motif Bio's skin disorder drug, iclaprim, has been denied approval by the US Food & Drug Administration (FDA) it was reported on Friday.
The product is intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
In the complete response letter, the US FDA stated that it cannot approve the company's New Drug Application (NDA) for the product in its present form. The regulator indicated to the company that additional data was required in the NDA to further evaluate the risk for liver toxicity prior to the drug's approval. The company stated that it will seek a meeting with the FDA as early as possible to explore potential options to address the shortcomings.
Iclaprim's NDA filed with the FDA included data from the REVIVE-1 and REVIVE-2 phase 3 trials in patients with ABSSSI. The product is a gram-positive investigational antibiotic. Its approval for the ABSSSI indication would make it eligible for 10 years of US market exclusivity.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT